Jennifer Fitzpatrick, Chief Legal Officer and Head of Program Management at Sionna Therapeutics, Inc. (NASDAQ:SION), filed a Form 4 on September 18, 2026, reporting two RSU grants and an option repricing effective September 17, 2026.

Key Highlights

  • Time-based RSU grant: Fitzpatrick received 28,133 restricted stock units at $0.0 cost, vesting on June 17, 2027, subject to continued service.
  • Performance-based RSU grant: An additional 28,132 RSUs were granted at $0.0 cost, vesting upon achievement of a designated performance milestone, subject to continued service.
  • Total common stock position: Following both grants, Fitzpatrick directly holds 56,265 shares of common stock.
  • Option repricing: A non-qualified stock option covering 103,140 shares was repriced from $39.21 to $7.18 per share, representing the fair market value on September 17, 2026.
  • Repricing retention period: If the repriced option is exercised before the retention period ends, the exercise price reverts to the original $39.21; the retention period ends on the earliest of March 17, 2028, a Sale Event, or certain qualifying terminations.
  • Board approval: According to the filing, the board of directors approved the option repricing effective September 17, 2026, under the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan.

RSU Awards and Option Repricing Details for Sionna Therapeutics CLO

According to the Form 4 filed by Jennifer Fitzpatrick, who serves as CLO and Head of Program Management at Sionna Therapeutics, two separate RSU grants were made on September 17, 2026. The first, covering 28,133 units, is a time-based award that vests on June 17, 2027, contingent on Fitzpatrick's continued service as of that date. The second, covering 28,132 units, is performance-based and vests upon achievement of a designated performance milestone, also subject to continued service. Each RSU represents a contingent right to receive one share of the issuer's common stock. Both grants were reported at a price of $0.0.

The filing also discloses an option repricing approved by the board of directors. A non-qualified stock option to purchase 103,140 shares of common stock, previously carrying an exercise price of $39.21 per share, was repriced to $7.18 per share, which the filing describes as "the fair market value per share of the Issuer's Common Stock on September 17, 2026." The repriced option has an expiration date of January 1, 2036, and all other terms remain unchanged. The filing notes the transactions were "exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."

A retention condition applies to the repriced option. According to the filing, if the option is exercised before the applicable retention period ends, the exercise price will revert to the original $39.21. The retention period begins on September 17, 2026, and concludes on the earliest of the 18-month anniversary of that date (March 17, 2028), a Sale Event as defined in the 2025 Plan, or certain qualifying terminations of service. Following the repricing, Fitzpatrick directly holds 103,140 derivative securities under the new exercise price, while the previously reported option at $39.21 shows a balance of zero.

What Was Disclosed

The filing reports two RSU grants totaling 56,265 shares and an option repricing on 103,140 shares from $39.21 to $7.18, all effective September 17, 2026, for Sionna Therapeutics CLO Jennifer Fitzpatrick.